Aquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Recommendation of “Hold” from Brokerages

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has earned an average recommendation of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $24.67.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. ValuEngine downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Canaccord Genuity set a $22.00 price objective on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, BidaskClub raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th.

Aquinox Pharmaceuticals (NASDAQ AQXP) remained flat at $$11.42 on Friday. 83,400 shares of the stock were exchanged, compared to its average volume of 67,159. Aquinox Pharmaceuticals has a 12 month low of $9.83 and a 12 month high of $19.97.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Tuesday, August 8th. The company reported ($0.59) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.59). equities research analysts forecast that Aquinox Pharmaceuticals will post -2.29 earnings per share for the current year.

Large investors have recently made changes to their positions in the stock. Archon Partners LLC grew its position in Aquinox Pharmaceuticals by 44.0% in the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after purchasing an additional 5,500 shares during the last quarter. Alps Advisors Inc. grew its position in Aquinox Pharmaceuticals by 4.7% in the 2nd quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock worth $297,000 after purchasing an additional 939 shares during the last quarter. Bank of New York Mellon Corp grew its position in Aquinox Pharmaceuticals by 16.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after purchasing an additional 3,299 shares during the last quarter. Sphera Funds Management LTD. bought a new position in Aquinox Pharmaceuticals in the 2nd quarter worth about $874,000. Finally, Northern Trust Corp grew its position in Aquinox Pharmaceuticals by 3.3% in the 2nd quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after purchasing an additional 2,691 shares during the last quarter. 95.15% of the stock is owned by institutional investors and hedge funds.

WARNING: “Aquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Recommendation of “Hold” from Brokerages” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://ledgergazette.com/2017/11/05/aquinox-pharmaceuticals-inc-aqxp-receives-consensus-recommendation-of-hold-from-brokerages.html.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply